WD-910
/ Wenda Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 27, 2025
A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=68 | Not yet recruiting | Sponsor: Zhejiang Wenda Medical Technology Co., Ltd.
New P1 trial
1 to 1
Of
1
Go to page
1